** Shares of biotechnology company AbCellera Biologics
ABCL.O up 1.8% at $5.22
** Co enters strategic collaboration with drugmaker Incyte
Corp INCY.O to discover and develop therapeutic antibodies in
oncology
** Under deal, Incyte has right to develop and commercialize
therapeutic antibodies resulting from collaboration
** ABCL to get research payments; also eligible to get
downstream clinical and regulatory milestone payments and
royalties on net sales of products
** Including session gains, ABCL stock down ~48.32% YTD
(Reporting by Judes Joseph in Bengaluru)
((Judes.joseph@thomsonreuters.com))